Floatz logo

egf816

Cancer

Cancer Research UKSmall moleculePhase 2/3Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
65/ 100

Competitive context

150 Active assets in the Cancer cohort.

Asset / SponsorPhaseRating
gsk1120212
Cancer Research UK
Phase 2/3BB
gw786034
University Hospital, Bordeaux
Phase 4BB
FENTANYL
M.D. Anderson Cancer Center
Phase 3BB
PANITUMUMAB
Amgen
Phase 4BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

egf816 is also rated in:

Carcinoma, Non-Small-Cell LungDormant
CCC
Indicative ·
52 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →